Vaccine Development for Epstein-Barr Virus.

[1]  Elizabeth M. Perez,et al.  Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice , 2016, Oncotarget.

[2]  B. Tabak,et al.  High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis , 2016, Journal of Virology.

[3]  C. Snapper,et al.  Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. , 2016, Vaccine.

[4]  R. Lin,et al.  Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits. , 2016, Vaccine.

[5]  M. Fitzpatrick,et al.  Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination , 2016, PLoS pathogens.

[6]  Chien-Jen Chen,et al.  High Levels of Antibody that Neutralize B-cell Infection of Epstein–Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma , 2016, Clinical Cancer Research.

[7]  H. Balfour,et al.  Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV , 2016, Clinical and Vaccine Immunology.

[8]  U. Baxa,et al.  Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site , 2015, Cell.

[9]  A. Rickinson,et al.  The immunology of Epstein-Barr virus-induced disease. , 2015, Annual review of immunology.

[10]  Robert E. White,et al.  Genome Diversity of Epstein-Barr Virus from Multiple Tumor Types and Normal Infection , 2015, Journal of Virology.

[11]  M. Caligiuri,et al.  The Epstein–Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development , 2015, Cancer Immunology Research.

[12]  R. Finberg,et al.  A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice , 2015, Journal of Translational Medicine.

[13]  M. Mar Albà,et al.  Genome-Wide Analysis of Wild-Type Epstein–Barr Virus Genomes Derived from Healthy Individuals of the 1000 Genomes Project , 2014, Genome biology and evolution.

[14]  C. Snapper,et al.  A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine. , 2013, Vaccine.

[15]  C. Rouzioux,et al.  Blood Epstein–Barr virus DNA load and risk of progression to AIDS‐related systemic B lymphoma , 2012, HIV medicine.

[16]  H. Varmus,et al.  Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention , 2011, Science Translational Medicine.

[17]  W. Hammerschmidt,et al.  A Virus-Like Particle-Based Epstein-Barr Virus Vaccine , 2011, Journal of Virology.

[18]  J. Cohen,et al.  Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and Reduces Viral Loads in Animals that Become Infected with Virus after Challenge , 2011, PLoS pathogens.

[19]  A. Rickinson,et al.  Cytotoxic CD4+ T Cell Responses to EBV Contrast with CD8 Responses in Breadth of Lytic Cycle Antigen Choice and in Lytic Cycle Recognition , 2011, The Journal of Immunology.

[20]  A. Ascherio,et al.  Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel , 2011, Multiple sclerosis.

[21]  G. Giovannoni,et al.  An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis , 2010, PloS one.

[22]  A. Ascherio,et al.  Primary infection with the Epstein‐Barr virus and risk of multiple sclerosis , 2010, Annals of neurology.

[23]  Jaap M Middeldorp,et al.  A Phase I Trial of Epstein-Barr Virus Gp350 Vaccine for Children With Chronic Kidney Disease Awaiting Transplantation , 2009, Transplantation.

[24]  D. Follmann,et al.  Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers , 2009, Journal of Virology.

[25]  T. Pierson,et al.  Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. , 2009, Virology.

[26]  Keiko Nagata,et al.  The evolution of Epstein-Barr virus inferred from the conservation and mutation of the virus glycoprotein gp350/220 gene , 2009, Virus Genes.

[27]  C. Sample,et al.  Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. , 2008, Frontiers in bioscience : a journal and virtual library.

[28]  M. Moutschen,et al.  Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. , 2007, The Journal of infectious diseases.

[29]  Andreas Suhrbier,et al.  Phase I Trial of a CD8+ T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis , 2007, Journal of Virology.

[30]  H. Haario,et al.  Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  A. Moosmann,et al.  Immunodominance of Lytic Cycle Antigens in Epstein-Barr Virus-Specific CD4+ T Cell Preparations for Therapy , 2007, PloS one.

[32]  Gary Dubin,et al.  Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. , 2007, Vaccine.

[33]  G. Mieli-Vergani,et al.  A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo. , 2006, The Journal of infectious diseases.

[34]  W. Hammerschmidt,et al.  Genetic design of an optimized packaging cell line for gene vectors transducing human B cells , 2006, Gene Therapy.

[35]  A. Moosmann,et al.  Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins , 2006, The Journal of experimental medicine.

[36]  A. Ascherio,et al.  Infectious mononucleosis and risk for multiple sclerosis: A meta‐analysis , 2006, Annals of neurology.

[37]  B. Walker,et al.  Differential targeting and shifts in the immunodominance of Epstein-Barr virus--specific CD8 and CD4 T cell responses during acute and persistent infection. , 2005, The Journal of infectious diseases.

[38]  A. Rickinson,et al.  CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells , 2005, The Journal of experimental medicine.

[39]  S. Hamilton-Dutoit,et al.  Characteristics of Hodgkin's lymphoma after infectious mononucleosis. , 2003, The New England journal of medicine.

[40]  M. Somasundaran,et al.  Differential Kinetics and Specificity of EBV-Specific CD4+ and CD8+ T Cells During Primary Infection1 , 2003, The Journal of Immunology.

[41]  Joel M. Palefsky,et al.  Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells , 2003, Nature Medicine.

[42]  R. Ahmed,et al.  SAP is required for generating long-term humoral immunity , 2003, Nature.

[43]  M. Caligiuri,et al.  Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. , 2002, Blood.

[44]  B. van der Holt,et al.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.

[45]  A. Rickinson,et al.  Epitope-specific Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus Infection , 2002, The Journal of experimental medicine.

[46]  S. L. Silins,et al.  Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. , 2001, Blood.

[47]  B. van der Holt,et al.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. , 2001, Blood.

[48]  Y. Jang,et al.  DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen. , 2001, Molecules and cells.

[49]  T. Rea,et al.  Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. , 2001, The Journal of the American Board of Family Practice.

[50]  W. Hammerschmidt,et al.  Infectious Epstein-Barr Virus Lacking Major Glycoprotein BLLF1 (gp350/220) Demonstrates the Existence of Additional Viral Ligands , 2000, Journal of Virology.

[51]  J. Cohen,et al.  Epstein-Barr virus infection. , 2000, The New England journal of medicine.

[52]  S. Burrows,et al.  EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. , 1999, Journal of immunology.

[53]  R. Spaete,et al.  Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. , 1999, Vaccine.

[54]  U. Prasad,et al.  The Epstein‐Barr Virus (EBV) major envelope glycoprotein gp350/220‐specific antibody reactivities in the sera of patients with different EBV‐associated diseases , 1998, International journal of cancer.

[55]  G. Ogg,et al.  Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.

[56]  R. Johnson,et al.  An animal model for acute and persistent Epstein-Barr virus infection. , 1997, Science.

[57]  A. Kumar,et al.  Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response , 1997, The Journal of experimental medicine.

[58]  Qingxue Li,et al.  The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells , 1995, Journal of virology.

[59]  J. Stewart,et al.  The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B. , 1993, Virology.

[60]  M. Perricaudet,et al.  Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. , 1993, The Journal of general virology.

[61]  J. Tarlton,et al.  Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. , 1992, The Journal of general virology.

[62]  E. Kieff,et al.  Early events in Epstein-Barr virus infection of human B lymphocytes. , 1991, Virology.

[63]  W. Schleif,et al.  Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine. , 1988, Virology.

[64]  M. Epstein,et al.  Recombinant vaccinia virus expressing epstein‐barr virus glycoprotein gp340 protects cottontop tamarins against EB virus‐induced malignant lymphomas , 1988, Journal of medical virology.

[65]  M. Epstein,et al.  Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. , 1986, Clinical and experimental immunology.

[66]  M. Epstein,et al.  Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccine , 1985, Nature.

[67]  J. Sklar,et al.  Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. , 1985, Science.

[68]  J. Edwards,et al.  Infectious mononucleosis-like response in common marmosets infected with Epstein-Barr virus. , 1984, The Journal of infectious diseases.

[69]  D. Thorley-Lawson,et al.  Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo , 1982, Journal of virology.

[70]  R. Chase,et al.  Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein. , 1982, Journal of immunology.

[71]  M. Epstein,et al.  Observations on the EB virus envelope and virus‐determined membrane antigen (MA) polypeptides , 1980, International journal of cancer.

[72]  D. Thorley-Lawson.  A virus-free immunogen effective against Epstein-Barr virus , 1979, Nature.

[73]  J. Cohen.  Primary Immunodeficiencies Associated with EBV Disease. , 2015, Current topics in microbiology and immunology.

[74]  H. Balfour,et al.  Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. , 2013, The Journal of infectious diseases.

[75]  C. Chu,et al.  First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. , 1995, Developments in biological standardization.

[76]  M. Epstein,et al.  Comparative immunogenicity studies on epstein‐barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton‐top tamarins , 1984, Journal of medical virology.